Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac

Atom Indonesia · Vol. 49 No. 1 (2023) · hlm. 27–32

DOI
10.55981/aij.2023.1203
ISSN
2356-5322, 0126-1568
Terbit
2023-03-29
Penerbit
National Research and Innovation Agency
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

Varian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence of the Halcyon 2.0 for quality assurance (QA) of head and neck cancer treatment planning, pretreatment, and treatment. The accuracy of the exit fluence for twenty treatment plannings has been evaluated by conducting gamma analysis for QA pretreatment and treatment in each field and composite field by using criteria for gamma index 3 %/3 mm and 2 %/2 mm. The QA pretreatment results are in the average value for each criterion for each field and composite fields on actual gantry angle and null gantry angle with gamma passing rate (GPR) of over 99 % (range 99.78 %-99.95 %) The total treatments consisted of 2717 fractions. The analysis results of GPR for fields were 99.32 % and 97.74 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. In addition, the analysis results of GPR for composites were 95.46 % and 81.38 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. Based on this result, the average GPRs of QA pretreatment are ≈ 99 % of the total pixels. This means the prediction dose of Varian Halcyon 2.0 is accurate. The average GPRs of treatment is nearly 90 %, showing that Varian Halcyon 2.0 is effective for creating treatment plans for complex cases.

Kata kunci

Jaringan kolaborasi para penulis

16 penulis · 43 tautan kepenulisan bersama · 15 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Kementerian Kesehatan Republik Indonesia
  • Dharmais Cancer Hospital
  • National Nuclear Energy Agency of Indonesia
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
B. DwinestiUniversity of Indonesia1
Dea RyanggaAfiliasi tidak diketahui1
F Y DimitriAfiliasi tidak diketahui1
Andrian Dede HandikaAfiliasi tidak diketahui1
M FadliKementerian Kesehatan Republik Indonesia1
Aloysius Mario Yudi PutrantoKementerian Kesehatan Republik Indonesia1
S SuharsonoDharmais Cancer Hospital1
A AzziUniversity of Indonesia1
V. VernandaUniversity of Indonesia1
K.Y.P. SandyNational Nuclear Energy Agency of Indonesia1
Djarwani Soeharso SoejokoUniversity of Indonesia1
S. LiuraUniversity of Indonesia1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://atomindonesia.brin.go.id/index.php/aij/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Dose Evaluation of Head and Neck Cancer IMRT Treatment Planning Based on Gamma Index Analysis of Varian Halcyon 2.0 Linac</dc:title>
	<dc:creator>Purwati, W.</dc:creator>
	<dc:creator>Suhaimi, F.</dc:creator>
	<dc:creator>Wibowo, W. E.</dc:creator>
	<dc:creator>Pawiro, S. A.</dc:creator>
	<dc:subject xml:lang="en-US">Halcyon 2.0; Head and neck cancer; Gamma index analysis; EPID-portal dosimetry</dc:subject>
	<dc:description xml:lang="en-US">Varian Halcyon 2.0 linear accelerator was launched and became available for clinical use in 2018. Therefore, it is necessary to evaluate the accuracy of exit fluence of the Halcyon 2.0 for quality assurance (QA) of head and neck cancer treatment planning, pretreatment, and treatment. The accuracy of the exit fluence for twenty treatment plannings has been evaluated by conducting gamma analysis for QA pretreatment and treatment in each field and composite field by using criteria for gamma index 3 %/3 mm and 2 %/2 mm. The QA pretreatment results are in the average value for each criterion for each field and composite fields on actual gantry angle and null gantry angle with gamma passing rate (GPR) of over 99 % (range 99.78 %-99.95 %) The total treatments consisted of 2717 fractions. The analysis results of GPR for fields were 99.32 % and 97.74 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. In addition, the analysis results of GPR for composites were 95.46 % and 81.38 % for gamma indexes of 3 %/3 mm and 2 %/2 mm, respectively. Based on this result, the average GPRs of QA pretreatment are ≈ 99 % of the total pixels. This means the prediction dose of Varian Halcyon 2.0 is accurate. The average GPRs of treatment is nearly  90 %, showing that Varian Halcyon 2.0 is effective for creating treatment plans for complex cases.</dc:description>
	<dc:publisher xml:lang="en-US">National Research and Innovation Agency</dc:publisher>
	<dc:contributor xml:lang="en-US">Universitas Indonesia</dc:contributor>
	<dc:date>2023-03-29</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://atomindonesia.brin.go.id/index.php/aij/article/view/1203</dc:identifier>
	<dc:identifier>10.55981/aij.2023.1203</dc:identifier>
	<dc:source xml:lang="en-US">Atom Indonesia; VOL 49, NO 1 (2023): APRIL 2023; 27-32</dc:source>
	<dc:source>2356-5322</dc:source>
	<dc:source>0126-1568</dc:source>
	<dc:source>10.55981/aij.v1i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/view/1203/1063</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/1203/2244</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/1203/2245</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/1203/2246</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/1203/2247</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/1203/2248</dc:relation>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>